| Literature DB >> 25136615 |
Signy Bendiksen1, Inigo Martinez-Zubiavrra2, Conny Tümmler3, Gunnar Knutsen4, Jan Elvenes4, Elisabeth Olsen3, Randi Olsen5, Ugo Moens6.
Abstract
The etiology of viruses in osteoarthritis remains controversial because the prevalence of viral nucleic acid sequences in peripheral blood or synovial fluid from osteoarthritis patients and that in healthy control subjects are similar. Until now the presence of virus has not been analyzed in cartilage. We screened cartilage and chondrocytes from advanced and non-/early osteoarthritis patients for parvovirus B19, herpes simplex virus-1, Epstein Barr virus, cytomegalovirus, human herpes virus-6, hepatitis C virus, and human endogenous retroviruses transcripts. Endogenous retroviruses transcripts, but none of the other viruses, were detected in 15 out the 17 patients. Sequencing identified the virus as HERV-WE1 and E2. HERV-W activity was confirmed by high expression levels of syncytin, dsRNA, virus budding, and the presence of virus-like particles in all advanced osteoarthritis cartilages examined. Low levels of HERV-WE1, but not E2 envelope RNA, were observed in 3 out of 8 non-/early osteoarthritis patients, while only 3 out of 7 chondrocytes cultures displayed low levels of syncytin, and just one was positive for virus-like particles. This study demonstrates for the first time activation of HERV-W in cartilage of osteoarthritis patients; however, a causative role for HERV-W in development or deterioration of the disease remains to be proven.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25136615 PMCID: PMC4130134 DOI: 10.1155/2014/698609
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Virus-specific primers used in this study.
| Virus | GenBank acc. number | Primer sequences | Position |
|---|---|---|---|
| HERVWE1 | |||
| Envelope (=syncytin) | NM_014590 | F: cat cga tag cac cca tca gat g | 13–34 |
| R: gag tga aat agc atg aaa aca g | 3025–3004 | ||
| ERVWE1 gag | AF156961 | F: tgt ccg ctg tgc tcc tga tc | 1–20 |
| R: ctg cgc cag tgt cca gga gac | 1921–1901 | ||
|
| |||
| HERVWE2 | |||
| Envelope | AF127228, | F: cca ata gcc aga cca tta tat ac | 1–23 |
| AF128229, | R: tgg ggt tcc att tgt aag acc | 1932–1912 | |
| ERVWE2 gag | AF123881 | F: cta gaa cgt att ctg gag aat tg | 2–24 |
| R: ggc tct caa tgg tca aac ata c | 1509–1488 | ||
|
| |||
| HHV-1 | GU734772 | F: tcc cca taa act ggg agt agc | 55192–55212 |
| R: cag aac tac agc gag ggc atc | 55327–55307 | ||
|
| |||
| HHV-6 | NC_000898 | F: gag tcc atg agt tag aag att | 150874–150894 |
| R: cta aat ttt cta cct ccg aaa tgt | 152099–152076 | ||
|
| |||
| HHV-4 (Epstein Barr) | V01555 | External primers | |
| F: agg gat gcc tgg aca caa ga | 48810–48829 | ||
| R: tgg tgc tgc tgg tgg tgg caa t | 49406–49385 | ||
| Nested primers | |||
| F: tcttgatag gga tcc gct agg ata | 48839–48862 | ||
| R: acc gtg gttbctg gac tat ctg gat | 49335–49311 | ||
|
| |||
| HHV-5 (human cytomegalovirus) | GQ222016 | External primers | |
| F: cag cac cat cct cct ctt cct ctg | 3665–3688 | ||
| R: cca agc ggc ctc tga taa cca agc | 4099–4076 | ||
| Nested primers | |||
| F: aga cac tgg ctc aga cct gac | 3708–3728 | ||
| R: aga gtc tgc tct cct agt gtg | 3989–3969 | ||
|
| |||
| Hepatitis C virus | AB691598 | External primers | |
| F: ggc gac act cca cca tgg atc ac | 16–38 | ||
| R: cat gtt gca cgg tct acg aga cc | 342–320 | ||
| Nested primers | |||
| F: ctg tga gga act tct gtc tt | 43–62 | ||
| R: ctc gca agc acc cta tca gg | 309–290 | ||
|
| |||
| Human parvovirus B19 | NC_000883 | External primers | |
| F: aat aca ctg tgg ttt tat ggg ccg | 1579–1602 | ||
| R: cca ttg ctg gtt ata acc aca ggt | 1862–1839 | ||
| Nested primers | |||
| F: aat gaa aac ttt cca ttt aat gat gta g | 1678–1705 | ||
| R: cta aaa tgg ctt ttg cag ctt cta c | 1780–1756 | ||
|
| |||
| Rabbit endogenous retrovirus (HRV5) | AF480924 | External primers | |
| F: tca ggt gct tca ttg gca gga tca | 3008–3031 | ||
| R: taa aat ttg tac ttt tgg gca ctg ctg | 3805–3782 | ||
| Nested primers | |||
| F: tgc aac ctt atg tta gtg cac tcc | 3052–3075 | ||
| R: tac tgc ctg gtc aac ata tag | 3766–3746 | ||
Figure 1Detection of human endogenous retrovirus sequences in chondrocytes and cartilage from OA patients. Total RNA was isolated and converted into cDNA. HERV sequences were amplified using degenerated primers complementary to sequences in the pro/pol genes of HRV-5 (Table 1) to obtain a ~1,000 bp fragment. Lane 1: DNA marker (in kb); lanes 2–4: OA8; lanes 4, 8, and 10: OA10; lanes 6–8: OA9; lane 11: OA2. Lanes 2, 8, and 9: RNA isolated from nitrogen-crushed cartilage; lanes 3, 7, and 10: RNA obtained from enzyme-digested cartilage; lanes 4–6 and 11: RNA purified from culture-expanded chondrocytes. PCR reactions were run on an agarose gel, stained with ethidium bromide, and the DNA was visualized under UV light. Cart.: cartilage; chond.: chondrocytes.
Figure 2Expression of ERVWE1 and ERVW2 in chondrocytes from OA and non- or early OA patients. (a) PCR on cDNA prepared from cultured chondrocytes isolated from knees or hip from OA patients. Specific primers for the ERVWE1 and ERVWE2 env gene (encoding syncytin) were used. (b) RNA purified from nitrogen-crushed cartilage. (c) RNA was isolated from chondrocytes obtained from 6 OA patients, converted into cDNA, and amplified using specific primers complementary to the gag gene of HERVWE1 (left panel) and HERVWE2 (right panel) sequences. (d) Amplification of cDNA prepared from chondrocytes from non- and early OA patients. Lanes 1 and 11: 1 kb plus ladder; lanes 2–10: amplified cDNA. The arrow indicates the presence of the amplified 3,000 bp of the ERVWE1 env transcript.
PCR results using HERV degenerated and ERVWE1- and ERVW2-specific primers.
| Patient group | ERVWE1 env | ERVWE2 env | ERVWE1 gag | ERVWE2 gag |
|---|---|---|---|---|
| OA | 15/17 (88%) | 15/17 (88%) | 5/6 (83%) | 5/6 (83%) |
| Non-/early OA | 3/8 (38%) | 0/8 (0%) | NT∗ | NT |
*NT: not tested.
Figure 3Alignment of the sequence of the 1,600 bp PCR products with ERVWE2 env transcript. Identical nucleotides are indicated by a vertical line, while point mutations are shown. The sequence obtained from OA8 patient has a deletion and insertion which restores the ORF.
Figure 4Presence of dsRNA and syncytin-1 in chondrocyte cultures obtained from OA and non- or early OA patients. Immunofluorescence assay with specific antibodies against dsRNA and syncytin was used. (a) Top row: chondrocytes from OA patients were examined for the presence of viral dsRNA by immunofluorescence using antibodies that specifically react with viral dsRNA. Middle row shows the expression of syncytin-1 in chondrocytes of the same OA patients. Bottom row: DAPI staining shows strong nuclear staining and weak cytoplasmic staining for nucleic acids. (b) Chondrocyte cultures from non-/early OA patients were monitored for the presence of dsRNA (top panel). Notice weak staining for dsRNA in chondrocytes from patient 3. Bottom row: DAPI staining.
Prevalence of dsRNA, syncytin-1, and HERV-like particles in samples from OA and non-/early OA patients.
| Material/method | IF syncytin | IF dsRNA | IEM syncytin | IEM dsRNA | TEM VLP | TEM budding |
|---|---|---|---|---|---|---|
| Chondrocytes OA | 20/22∗ (S)∗∗ | 20/22 (S) | 7/7 (S) | 7/7 (S) | 6/7 | 5/7 |
| Cartilage OA | 7/7 (S) | 7/7 (S) | 22/24 | 16/24 | ||
| Chondrocytes non-OA | 4/7 (3 W, 1 S) | 3/7 (2 W, 1 S) | 4/7 (3 W, 1 S) | 3/7 (2 W, 1 S) | 1/8 | |
| Cartilage non-OA | 3/5 (2 W, 1 S) | 3/5 (2 W, 1 S) | ||||
| Collagenase-treated supernatants OA | 3/4 |
*Number of positive samples/total number of samples.
∗∗S: strong staining; W: weak staining; VLP: virus-like particles.
Figure 5Detection of dsRNA and syncytin-1 in chondrocyte cultures obtained from OA patients by IEM. (a) IEM on samples from OA patients. Panels A and A′: cryo-IEM shows the presence of syncytin in the nucleus and cytoplasm (arrow heads). CP: cytoplasm; CM: nuclear membrane; MT: mitochondrion; n: nucleus. Panels B and B′: detection of dsRNA. Panel C illustrates that dsRNA (small dots) and syncytin (large dots) colocalize. (b) Cryo-IEM of virus dsRNA in early or non-OA patients (ACI). Panel A shows a completely negative sample and represents two out of five tested chondrocyte cultures. Panel B: example of very low levels of dsRNA detected in chondrocyte culture of a non-OA patient. Panel C: chondrocyte culture from one of the non-/early OA patients expressed relatively high levels of dsRNA. The insert depicts structures resembling virus budding (marked with an asterisk). (c) Western blot performed on lysates prepared from chondrocytes isolated from OA patients. The expression of syncytin-1 was monitored using syncytin-1 specific antibodies. A band of ~55 kDa which corresponds to the theoretic molecular mass of syncytin-1 is visible in all lysates. Lane 1: protein marker (in kDa); lanes 2–6: chondrocyte lysates.
Figure 6Retrovirus-like particles in cartilage of OA patients. Transmission EM (a, b, and d) and negative staining EM (c) were used to monitor the presence of virus-like particles in cartilage samples from OA patients. Negative staining EM was performed on collagenase-treated cartilage, and the resulting subcellular bodies were absorbed into grids. (d) Immune-gold labeling of viruses with antibodies against envelope protein syncytin. The size bar is indicated.